<DOC>
	<DOCNO>NCT01609257</DOCNO>
	<brief_summary>The purpose study determine whether norovirus vaccine effective prevent acute gastroenteritis due experimental human Norovirus GII.4 challenge dose . The purpose also evaluate safety vaccine immunogenicity vaccine .</brief_summary>
	<brief_title>Norovirus Bivalent-Vaccine Efficacy Study</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>To eligible participate study , subject must meet following criterion : 1 . Signed informed consent . 2 . Age 18 50 year ( e.g. , reach 50th birthday ) . 3 . Good general health determine screen evaluation within 45 day randomization . 4 . Expressed interest , availability , understand fulfill study requirement include measure prevent Norovirus contamination environment spread infection illness community . The prospective subject must pass ( ≥70 % correct answer ) write examination aspect study enrollment . 5 . Available return followup visit follow discharge inpatient unit able deliver stool specimen investigative site promptly plan move within duration study . 6 . Female subject must nonchildbearing potential , childbearing potential ( determined investigator ) must practice abstinence use effective license method birth control ( e.g . oral contraceptive ; diaphragm condom combination contraceptive jelly , cream , foam ; intrauterine contraceptive device , DepoProvera ; skin patch ; vaginal ring cervical cap ) 30 day prior vaccination must agree continue precaution study 60 day Challenge visit . Male subject must agree father child day vaccination 60 day Challenge visit . 7 . Have serum antibody titer ≤1:1600 GII.4 Norovirus challenge strain measure Immunoglobulin G ( IgG ) P Particle EnzymeLinked Immunosorbent Assay ( ELISA . ) 8 . Demonstrated H Type 1 secretor positive Histoblood Group Antigen ( HBGA ) bind assay saliva test . [ This saliva test may do anytime prior enrollment need repeat . ] 9 . Negative serology hepatitis C antibody , Human Immune Deficiency Virus ( HIV ) antibody , hepatitis B surface antigen , Rapid Plasma Reagin ( RPR ) . 10 . Agrees participate another clinical trial investigational product duration study ( 12 month last dose study vaccine placebo i.e . 393 day ) . To eligible participate study , subject must NOT meet follow criterion : 1 . Living daily contact child age 5 year less woman know pregnant . This include significant contact home , school , daycare , equivalent facility . 2 . Nursing mother . 3 . Living daily contact childcare worker . 4 . Living daily contact elderly person age 70 year , infirmed , diapered individual , person disability incontinent person . This include work visit nurse home daycare equivalent facility . 5 . History gastroenteritis suggestive Norovirus illness since screen serum antibody IgG P Particle ELISA test do . 6 . History gastroenteritis within past 2 week . 7 . History chronic functional dyspepsia , chronic gastroesophageal reflux disease , peptic ulcer disease , gastrointestinal hemorrhage , gall bladder disease , inflammatory bowel disease , irritable bowel syndrome , frequent diarrhea , chronic constipation , malabsorption , maldigestion , major Gastrointestinal ( GI ) surgery , diverticulitis anytime subject 's lifetime chronic GI disorder would interfere interpretation symptom evaluation study . 8 . Routine use medication oral contraceptive agent , antihypertensive , antidepressant , vitamin mineral . The use medication discuss Sponsor and/or Central Safety Monitor ( CSM ) . 9 . History follow medical illness : Immunosuppression ( disease treatment may affect immune system function ) Diabetes ( include gestational diabetes pregnancy require treatment dietary ) . Cancer ( malignancy resolve excised skin lesion ) . Heart disease ( hospitalization heart attack , arrhythmia , syncope ) Unconsciousness ( single brief `` concussion '' ) Seizures ( febrile seizure child &lt; 5 year old ) Asthma require treatment inhaler medication past 2 year . Neuroinflammatory disease Autoimmune disease Eating disorder Chronic headache associate vomit Chronic vomit syndrome 10 . Any current illness require daily medication vitamin , mineral , birth control , antihypertensives antidepressant . The use medication discuss Sponsor and/or CSM . 11 . Allergies hypersensitivity component vaccine challenge virus . 12 . Any clinically significant abnormality detect physical examination , include : Murmur ( functional , ie normal , murmur ) Focal neurological abnormality Hepatosplenomegaly Lymphadenopathy Jaundice 13 . Hypertension define BP &gt; 150/90 mm Hg two separate measurement . Chronic stable wellcontrolled hypertension medication allow . 14 . History 3 hospitalization invasive bacterial infection ( pneumonia , meningitis ) , acute chronic dermatitis ( e.g . eczema , seborrhea , psoriasis ) collagen vascular disease ( e.g . Systemic Lupus Erythematosus ( SLE ) dermatomyositis ) . 15 . Presence serious chronic illness . 16 . Positive stool/fecal culture bacterial pathogen ( salmonella , campylobacter , E. coli 0157 : H7 , yersinia , shigella ) positive stool/fecal screen ovum parasite . 17 . Employment food service industry , restaurant cafeteria facility . Specifically , include person whose employment require food process 4 week follow challenge . 18 . Healthcare worker patient contact expect 4 week follow challenge . 19 . Expected contact ( employment home ) immunocompromised person ( HIVpositive , receive immunosuppressive medication oral steroid antineoplastic agent ) 4 week follow challenge . 20 . Employment airline flight attendant schedule work 4 week follow challenge . 21 . Persons plan take cruise 4 week follow challenge . 22 . Persons plan live confine environment ( e.g . ship , camp , dormitory ) within 4 week follow challenge . 23 . Persons consume plan consume raw shellfish ( e.g . oyster ) screen post challenge Day 30 . 24 . Any following lab abnormality ( per site local laboratory ) : Absolute neutrophil count ( ANC ) outside normal range Total White Blood Cell Count ( WBC ) outside normal range Hemoglobin hematocrit outside normal range Platelet count outside normal range Electrolytes [ Sodium ( Na ) , Potassium ( K ) , Chloride ( Cl ) , Carbon dioxide ( CO2 ) ] , Blood Urea Nitrogen ( BUN ) and/or creatinine outside normal range Screening glucose &gt; upper limit normal ( ULN ) . Fasting glucose require Alanine aminotransferase ( ALT ) , Aspartate aminotransferase ( AST ) , alkaline phosphatase , bilirubin ( total indirect ) , Gamma Glutamyl Transferase ( GGT ) outside upper limit normal range Screening urinalysis value high `` trace '' positive urine protein urine glucose , urine Red Blood Cells ( RBCs ) ( ≥3 ; woman menses ) . All lab may repeat outside normal limit . If repeat continue outside site normal range , may enroll determine Principal Investigator ( PI ) clinically significant discuss Sponsor and/or CSM . 25 . For woman child bear potential , positive serum pregnancy test within 14 day positive urine pregnancy test within one day randomization . 26 . Temperature &gt; 100.4°F orally , symptom acute selflimited illness upper respiratory infection within 3 day administer either dose Norovirus Bivalent VLP vaccine placebo control challenge product . 27 . Resting heart rate &gt; 100 beat per minute &lt; 55 beat per minute , respiratory rate ≥ 20 breath per minute . If heart rate &lt; 55 beat per minute investigator determine clinically significant heart rate increase &gt; 55 beat per minute moderate exercise , subject exclude . Vital sign may repeat . 28 . Clinically abnormal screen electrocardiogram ( ECG ) define pathologic Q wave significant STT wave change ; criterion leave ventricular hypertrophy ; nonsinus rhythm exclude isolated premature atrial contraction . 29 . Previous participation study experimental norovirus infection norovirus vaccine . 30 . Study site personnel family member 31 . Significant history psychiatric hospitalization , alcohol abuse , illicit drug use . 32 . Receipt license live vaccine within 28 day license inactivated vaccine within 14 day administration either dose vaccine placebo challenge product . 33 . Completion investigational vaccine drug study within 7 day randomization . 34 . Receipt systemic corticosteroid great 7 day within past six month . 35 . Regular use laxatives antimotility agent . 36 . Receipt blood blood product within past six month . 37 . Subjects unwilling unable cease smoke entry inpatient facility discharge inpatient facility . 38 . Other condition clinical judgment investigator would jeopardize safety right subject participate trial , would render subject unable comply protocol , would interfere evaluation Vaccination stage evaluation Challenge stage . Challenge Stage Exclusion Criteria The following additional exclusion criterion must meet prior admission inpatient unit Challenge : 1 . Use antibiotic within 7 day prior entry inpatient challenge facility . 2 . Use H2 receptor antagonist ( e.g . Tagamet , Zantac , Pepcid ) , proton pump inhibitor ( e.g . Prilosec , Protonix , Prevacid ) , prescription acid suppression medication counter antacid within 72 hour challenge . 3 . Use prescription Over Counter ( OTC ) medication contain acetaminophen , aspirin , ibuprofen , and/or nonsteroidal antiinflammatory drug within 48 hour prior challenge .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>